The sheer volume and pace of biotech offerings are causing some to question whether the sector is nearing the end of its years of buoyancy.
Companies making headlines before the bell Monday.
Stocks declined on Tuesday, extending losses into a second session, as oil rebounded from a five-year low.
Toss 'em in your kids' stocking, or be a Grinch and keep them. "Mad Money" host Jim Cramer says buy 'em either way.
Jim Cramer has a personal connection to why he approves of Merck's acquisition of Cubist. Find out why.
Stocks declined Monday as trade numbers from China came in below expectations and oil companies were knocked by the falling price of crude.
Drug giant Merck said it will buy Cubist and its slate of medicines administered in hospitals, many for bacterial infections, for about $9.5 billion.
Some of the names on the move ahead of the open.
Drug giant Merck is in talks to acquire antibiotics maker Cubist for about $102 a share in cash, according to people familiar with the matter.
The CNBC RQ 50 identifies companies that don't just spend big on R&D, but spend right, creating return on innovation for shareholders.
Fed Chair Janet Yellen highlights that some sectors, like social media and biotech, are seeing stretched valuations.
Cubist Pharmaceuticals is focused on treatments for fighting superbugs, an area many drug developers are avoiding. But its success may attract their attention.
Cubist Pharmaceutical CEO Michael Bonney talks to CNBC's Bertha Coombs about his company's big bet on antibiotics to treat superbugs, which recently drove the firm to acquire two smaller rivals. He leaves the door open to future deals.
Some of Monday's midday movers.
Check out which companies are making headlines after the bell Wednesday:
Big pharma is abandoning antibiotic research at a time when fears over superbugs are growing at an alarming rate, leaving smaller firms to fill the breach.
It’s time for the Lightning Round. Cramer makes the call on viewer favorites.
LEXINGTON, Mass.-- Cubist Pharmaceuticals Inc. said Thursday that its net income rose 66 percent in the third quarter on greater sales of its antibiotic Cubicin and other products, and lower tax costs. The company said its net income grew to $40.3 million, or 55 cents per share, in the three months through Sept. 30, from $24.2 million, or 33 cents per share, a year ago.
Oct 9- Cubist Pharmaceuticals Inc:. *RBC raises Cubist Pharmaceuticals Inc price target to $52 from $50;. Reuters Station users, click. 1568.
Check out which companies are making headlines after the bell Wednesday.